Form 4: Cabaletta Bio CEO Steven Nichtberger Receives Repriced Stock Options
SEC Form 4
Cabaletta Bio's CEO, Steven Nichtberger, had his stock options repriced by the company's board of directors, effective May 19, 2025.
Summary
- On May 19, 2025, Cabaletta Bio's board of directors approved a repricing of stock options held by CEO Steven Nichtberger.
- The repricing became effective on the same day.
- The exercise price of the options was adjusted to $1.92 per share, reflecting the fair market value of Cabaletta Bio's common stock on the repricing date.
- The repriced options are subject to a retention period, during which the original exercise price will apply if the options are exercised.
- The retention period ends one year after the repricing date, upon a sale event, or upon termination of the reporting person's service due to death or disability.
- The repricing involved multiple stock option grants with varying original exercise prices and expiration dates.
- The total number of options repriced was 1,977,814.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The repricing could be seen as slightly positive as it incentivizes management, but also reflects a potentially lower stock price than when the original options were granted.
Positives
- The repricing aligns the CEO's incentives with the current market value of the company's stock.
- The retention period encourages continued service and commitment from the CEO.
Risks
- If the CEO leaves the company before the end of the retention period, the repriced options could revert to their original, potentially higher, exercise prices.
Future Outlook
The document does not contain specific forward-looking statements beyond the terms of the option repricing.
Industry Context
Option repricing is a common practice in the biotech industry to retain key executives, especially when a company's stock price has declined. It aims to re-incentivize management by adjusting the exercise price of options to reflect the current market conditions.
Comparison to Industry Standards
- Option repricing is a fairly common practice, particularly in volatile sectors like biotechnology.
- Companies like Amgen, Gilead Sciences, and Biogen have all used similar strategies to retain key personnel during periods of stock price underperformance.
- The specific terms of the repricing, such as the retention period, are generally in line with industry standards to ensure continued commitment from the executive.
Stakeholder Impact
- Shareholders may view the repricing positively if it leads to improved company performance due to incentivized management.
- Employees may see the repricing as a sign of the company's commitment to retaining key personnel.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Issuer's board of directors approved an option repricing. |
| 05/19/2025 | Date of Earliest Transaction, Repricing Date, and Effective Date of the option repricing. |
| 10/23/2029 | Expiration date of some of the stock options. |
| 02/28/2030 | Expiration date of some of the stock options. |
| 02/28/2031 | Expiration date of some of the stock options. |
| 01/17/2032 | Expiration date of some of the stock options. |
| 01/17/2033 | Expiration date of some of the stock options. |
| 02/28/2034 | Expiration date of some of the stock options. |
Keywords
stock options, repricing, Cabaletta Bio, CEO, Steven Nichtberger, equity compensation, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.